The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary

Sep 24, 2026

Fertility-preserving treatment for young women with synchronous primary neoplasm of the endometrium and ovary is evaluated through a retrospective review of eight patients treated at Fudan University between April 2016 and December 2022. Patients included concurrent primary grade 1 presumed stage IA endometrioid endometrial adenocarcinoma or endometrial atypical hyperplasia with primary stage I ovarian tumors. Results show 87.5% achieved complete response without recurrence signs; 4 of 5 pregnancies and successful deliveries occurred. Conclusion emphasizes feasibility with strict screening, monitoring, informed consent, and need for longer follow-up.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Abstract

Purpose

Methods

Results

Conclusion

Introduction

Background and rationale

Methods

Gama et al. Journal of Ovarian Research (2023) 16:235 [https://doi.org/10.1186/s13048-023-01316-w](https://doi.org/10.1186/s13048-023-01316-w) Journal of Ovarian Research RESEARCH Open Access The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary Qujia Gama1,2†, Shuhan Luo1,2†, Pengfei Wu1,2, Lulu Wang1,2, Sijia Liu1,2, Hongwei Zhang2,3, Li Sun2,4, Yiqin Wang2,5, Min Yu2,6, Xiaojun Chen1,2*, Weiwei Shan1,2* and Xuezhen Luo 1,2* Abstract Purpose To investigate the efficacy of fertility-preserving treatment for young women with synchronous primary neoplasm of endometrium and ovary. Methods We retrospectively reviewed eight patients with concurrent primary grade 1 presumed stage IA endometrioid endometrial adenocarcinoma (EEA) or endometrial atypical hyperplasia (EAH) and primary stage I ovarian tumors who underwent fertility-sparing treatment in the Obstetrics and Gynecology Hospital of Fudan University between April 2016 and December 2022. Results Synchronous endometrial and ovarian cancers (SEOC) accounted for 50% of these eight patients. The median age of patients was 30.5 years (range, 28–34 years) . None of them received chemotherapy. The median treatment time was 4 months (range, 3–8 months) . 87. 5%(7/8) cases achieved complete response (CR), and the median time to CR was 3.8 months (range, 1.5–7. 7 months) . Among patients who got CR, none of them showed any signs of recurrence. Pregnancies and successful deliveries were achieved in 4 of 5 patients. Till September 2023, the median follow-up period was 50.5 months (range:15 .2–85.2 months) . Conclusion Fertility-sparing treatment is feasible for highly selected patients with synchronous neoplasm of the endometrium and ovary, but strict screening and monitoring are mandatory. Though the results of our limited cases are encouraging, long follow-up and more clinical data are required. Enrolled patients must be fully informed of the risks during conservative treatment. Keywords Fertility-sparing treatment, Synchronous endometrial and ovarian neoplasm, Synchronous endometrial and ovarian cancers (SEOC), Endometrial cancer (EC), Ovarian cancer (OC) †Qujia Gama and Shuhan Luo equally contributed to this study and were the first authors. *Correspondence: Xiaojun Chen [xiaojunchen2013@sina.com](xiaojunchen2013@sina.com)[ ](xiaojunchen2013@sina.com)Weiwei Shan [fdsww1024@sina.cn](fdsww1024@sina.cn)[ ](fdsww1024@sina.cn)Xuezhen Luo [xuezhenluo2013@163.com](xuezhenluo2013@163.com) Full list of author information is available at the end of the article © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Gama

FAQs

What is the purpose of the study?

To investigate the efficacy of fertility-preserving treatment for young women with synchronous primary neoplasm of the endometrium and ovary.

How were patients managed and what study design was used?

A single-institution retrospective review of eight young patients who underwent fertility-sparing treatment between April 2016 and December 2022.

What were the key outcomes for oncology response and recurrence?

Complete response was achieved in 87.5% (7/8) with a median time to complete response of 3.8 months, and no recurrence signs were observed among those achieving complete response.

What did the study report about pregnancy and follow-up?

Pregnancies and successful deliveries occurred in 4 of 5 patients who achieved complete response; the median follow-up up to September 2023 was 50.5 months.

Sep 24, 2026

Upload by Well Done